TLSA Stock Summary and Trading Ideas (Tiziana Life Sciences - Common Shares | NASDAQ:TLSA)

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Tiziana Life Sciences - Common Shares trades on the NASDAQ stock market under the symbol TLSA.

As of September 18, 2026, TLSA stock price declined to $0.91 with 397,029 million shares trading.

TLSA has a beta of 0.91, meaning it tends to be less sensitive to market movements. TLSA has a correlation of 0.03 to the broad based SPY ETF.

TLSA has a market cap of $115.24 million. This is considered a Micro Cap stock.

In the last 3 years, TLSA traded as high as $2.60 and as low as $.41.

TLSA has underperformed the market in the last year with a price return of -49.1% while the SPY ETF gained +16.8%. TLSA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -21.9% and -11.2%, respectively, while the SPY returned +2.3% and -0.9%, respectively.

TLSA support price is $.91 and resistance is $1.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TLSA shares will trade within this expected range on the day.